Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-Labeled M5A Antibody PET in Diagnosing CEA Positive Cancers
NCT02293954Active, not recruiting
- Sponsor
- City of Hope
- Start
- Nov 2015
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Copper Cu 64 anti-CEA monoclonal antibody M5A in carcinoma, sponsored by City of Hope. Primary endpoint: Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2. Started Nov 2015; status: active, not recruiting.
02
Drugs
Copper Cu 64 anti-CEA monoclonal antibody M5A
03
Conditions
carcinoma
Beyond the preview
Go deeper on NCT02293954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293954.